MedTrace Logo

Combination Pharmacological Interventions for Multiple Mechanisms of Obstructive Sleep Apnea

NCT03892772 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2022-03-02

No results posted yet for this study

Summary

Currently, there is no pharmacological intervention for OSA that targets multiple pathophysiological deficits in combination. Here the investigators study the effect on sleep apnea severity of combinations of pharmacological agents that stimulate the pharyngeal muscles, stabilize ventilatory control, and increase the arousal threshold.

Conditions

Interventions

DRUG

SAS0421a

treatment will be given for 3 days

DRUG

SAS0421b

treatment will be given for 3 days

DRUG

SAS0421c

treatment will be given for 3 days

DRUG

placebo

placebo will be given for 3 days

Sponsors & Collaborators

  • Apnimed

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Scott A Sands, PhD · Brigham and Women's Hospital

  • Bradley A Edwards, PhD · Monash University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-14
Primary Completion
2021-07-03
Completion
2021-07-03
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03892772 on ClinicalTrials.gov